Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EndoStim Neurostim System Gains Breakthrough Status to Treat GERD - Medical Product Outsourcing
OEM News

EndoStim Neurostim System Gains Breakthrough Status to Treat GERD

Implantable neurostimulation treatment for drug-refractory gastroesophageal reflux disease (GERD).

EndoStim has gained U.S. Food and Drug Administration (FDA) breakthrough status for its EndoStim implantable neurostimulation system to treat drug refractory gastroesophageal reflux disease (GERD).
 
The designation aims to provide more timely access to medical devices for more effective treatment/diagnosis of life-threatening or irreversibly debilitation conditions. The status speeds up development, assessment, and review.
 
“We are pleased that the FDA has recognized the therapeutic potential of the EndoStim System as a new treatment in development for drug refractory GERD,” Eric Goorno, CEO of EndoStim told the press. “Our goal is to bring this new therapy to patients as quickly as possible. We look forward to working closely with the FDA to expedite the review of the EndoStim System.”

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters